Astragaloside I

CAS# 84680-75-1

Astragaloside I

Catalog No. BCN5961----Order now to get a substantial discount!

Product Name & Size Price Stock
Astragaloside I:5mg $58.00 In Stock
Astragaloside I:10mg Please Inquire Instock
Astragaloside I:20mg Please Inquire Instock
Astragaloside I:50mg Please Inquire Instock
Molarity Calculator Dilution Calculator Send Mail Directly

Quality Control of Astragaloside I

Quality Control & MSDS

Number of papers citing our products

Chemical structure

Astragaloside I

3D structure

Chemical Properties of Astragaloside I

Cas No. 84680-75-1 SDF Download SDF
PubChem ID 13996685 Appearance White-beige powder
Formula C45H72O16 M.Wt 869.1
Type of Compound Triterpenoids Storage Desiccate at -20°C
Synonyms Astrasieversianin IV; Cyclosieversioside B;91739-00-3
Solubility DMSO : 50 mg/mL (57.53 mM; Need ultrasonic)
H2O : < 0.1 mg/mL (insoluble)
Chemical Name [(2S,3R,4S,5R)-3-acetyloxy-5-hydroxy-2-[[(1S,3R,6S,8R,9S,11S,12S,14S,15R,16R)-14-hydroxy-15-[(2R,5S)-5-(2-hydroxypropan-2-yl)-2-methyloxolan-2-yl]-7,7,12,16-tetramethyl-9-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-pentacyclo[9.7.0.01,3.03,8.012,16]octadecanyl]oxy]oxan-4-yl] acetate
SMILES CC(=O)OC1C(COC(C1OC(=O)C)OC2CCC34CC35CCC6(C(C(CC6(C5CC(C4C2(C)C)OC7C(C(C(C(O7)CO)O)O)O)C)O)C8(CCC(O8)C(C)(C)O)C)C)O
Standard InChIKey KXHCYYSIAXMSPA-OOCCOBHWSA-N
Standard InChI InChI=1S/C45H72O16/c1-21(47)56-33-24(50)19-55-38(34(33)57-22(2)48)60-28-11-13-45-20-44(45)15-14-41(7)35(43(9)12-10-29(61-43)40(5,6)54)23(49)17-42(41,8)27(44)16-25(36(45)39(28,3)4)58-37-32(53)31(52)30(51)26(18-46)59-37/h23-38,46,49-54H,10-20H2,1-9H3/t23-,24+,25-,26+,27-,28-,29-,30+,31-,32+,33-,34+,35-,36-,37+,38-,41+,42-,43+,44-,45+/m0/s1
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Source of Astragaloside I

The root of Astragalus membranaceus (Fisch.) Bunge

Biological Activity of Astragaloside I

DescriptionAstragaloside Ι may protect the cerebral tissue against the free radical damage in ischemia and inhibit the activation of BV-2 cells induced by LPS through suppressing the activation of PI3K/Akt/NF-κB pathway. It stimulates osteoblast differentiation through the Wnt/β-catenin signaling pathway, which also activates the BMP pathway and RANK pathway.
TargetsWnt/β-catenin | HIF | TNF-α | NO | NOS | COX | NF-kB | PI3K | Akt | NF-kB | IkB | IL Receptor | IKK
In vitro

Astragaloside I Stimulates Osteoblast Differentiation Through the Wnt/β-catenin Signaling Pathway.[Pubmed: 27397144 ]

Phytother Res. 2016 Oct;30(10):1680-8.

Astragaloside I (As-I), one of the main active ingredients in Astragalus membranaceus, is believed to have osteogenic properties, but this hypothesis has not been investigated in detail.
METHODS AND RESULTS:
In the present work, the As-I-induced osteogenic effects and its underlying mechanism were studied in MC3T3-E1 cells. The results indicated that the cellular levels of ALP and extracellular matrix calcium increased in a dose-dependent manner by As-I. To clarify the mechanisms involved in this process, the effect of As-I on the key osteogenic-related genes was investigated. We found that As-I stimulated the expression of β-catenin and Runx2 in MC3T3-E1 cells, which play central roles in the Wnt/β-catenin signaling pathway, suggesting that As-I could promote osteoblastic differentiation by regulating the Wnt/β-catenin signaling pathway. Moreover, the osteogenic effect of As-I could be inhibited by DKK-1, which is the classical inhibitor of Wnt/β-catenin-signaling pathway. Furthermore, As-I also increased BMP-2, BGP and OPG/RANKL expression, which are also activated by Wnt/β-catenin signaling pathway.
CONCLUSIONS:
Taken together, our findings show that As-I stimulates osteoblast differentiation through the Wnt/β-catenin signaling pathway, which also activates the BMP pathway and RANK pathway, thus highlighting the As-I for pharmaceutical and medicinal applications such as treating bone disease.

In vivo

Protective effects of astragalus extract against intermittent hypoxia-induced hippocampal neurons impairment in rats.[Pubmed: 23595393]

Chin Med J (Engl). 2013;126(8):1551-4.

Intermittent hypoxia is the main pathophysiological cause of the obstructive sleep apnea syndrome. Astragalus shows improvement of spatial learning and memory abilities under intermittent hypoxia. Our study aimed to investigate the protective effect of astragalus against intermittent hypoxia induced-hippocampal neurons impairment in rats and lay the theoretical foundation for the sleep apnea improvement in cognitive function by astragalus.
METHODS AND RESULTS:
Male Wistar rats were divided into 4 groups: blank control group, normoxia group, intermittent hypoxia group and astragalus treated intermittent hypoxia group. After 6-week treatment, apoptosis of neurons was evaluated by terminal deoxynucleotidyl-transferase-mediated dUTP nick end-labeling (TUNEL) assay. Furthermore, the expression of HIF-1a was detected by real-time reverse transcription polymerase chain reaction (RT-PCR) at the mRNA level as well as by immunohistochemistry (IHC) and Western blotting at the protein level. HPLC analysis indicated that Astragaloside IV, Astragaloside II and Astragaloside I were the main compounds in astragals extract. Astragalus extract reduced the apoptosis of hippocampal neurons (P < 0.05) and decreased the expression of HIF-1a at both the mRNA and protein levels in hippocampus compared with non-treated groups (P < 0.05).
CONCLUSIONS:
Astragalus protects against intermittent hypoxia-induced hippocampal neurons impairment in rats.

Protocol of Astragaloside I

Cell Research

Astragaloside I inhibited the activation of BV-2 cell induced by LPS through modulation of PI3K/Akt/NF-κB pathway[Reference: WebLink]

China Journal of Traditional Chinese Medicine & Pharmacy, 2016(05).

To investigate the effect and mechanism of Astragaloside I(AST I) on the activation of microglial cell line BV-2 induced by LPS.
METHODS AND RESULTS:
After pre-treated with AST I(25, 50, 100μmol/L) for 2 h, BV-2 cells were stimulated with LPS(200ng/m L) for 20 h. Thereafter, the cells and the culture medium were collected. Cell viability was measured by CCK-8 method. Concentration of TNF-α was detected by using ELISA kit. Secretion of NO in medium was assayed with Greiss approach. Gene expressions of CD11 b, TNF-α, i NOS, and IL-1β m RNA were detected with quantitative PCR. Protein expression of PI3K/Akt/NF-κB pathway was detected using Western blotting assay. Neuclear translocation of p-NF-κB was monitored with immunocytochemistry. AST I inhibited the secretion of TNF-α and NO on BV-2 cells upon LPS stimulation(P0.001) without affecting cell viability. It could prevent the up-regulation of gene expressions of TNF-α, i NOS and IL-1β(P0.001, P0.001, P0.05) but not that of CD11 b. Meanwhile, AST I suppressed the increase of i NOS and COX-2 protein induced by LPS. Further study disclosed that AST I reduced nuclear translocation of activated NF-κB and deceased phosphorylation of PI3 K, Akt, NF-κB, and IκB.
CONCLUSIONS:
Astragaloside I inhibited the activation of BV-2 cells induced by LPS through suppressing the activation of PI3K/Akt/NF-κB pathway, therefore, reduced the nuclear translocation of phosphorylated NF-κB, leading to the down-regulation of the gene expressions of TNF-α, i NOS and IL-1β and thus lessened the production of i NOS, TNF-α and COX-2 protein.

Animal Research

Effects of Astragaloside I on Cerebral GSH-px and MDA Contents Following Middle Cerebral Artery Occlusion in Mice[Reference: WebLink]

Chinese Journal of Clinical Neurosciences, 1998(03):146-8.

Free radicals formation and lipid peroxidation were thought to potentiate ischemic brain cell injury.
METHODS AND RESULTS:
In the present study DTNB method and a-thiobarbituric acid method were applied to measure the activity of GSH-px and the concentration of MDA respectively following MCAO in mice. The results showed that there was no significant difference in cerebral GSHpx activity between ischemic group and sham operated group, while MDA concentration markedly increased in ischemic group compared with the sham operated group (P0. 01). Injection of Astragaloside I intraperitoneally at 1 hour before the MCAO mildly enhanced GSH-px activity, but markedly decreased MDA concentration (P0. 01).
CONCLUSIONS:
These facts suggest that Astragaloside I might protect the cerebral tissue against the free radical damage in ischemia.

Astragaloside I Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

Astragaloside I Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of Astragaloside I

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 1.1506 mL 5.7531 mL 11.5062 mL 23.0123 mL 28.7654 mL
5 mM 0.2301 mL 1.1506 mL 2.3012 mL 4.6025 mL 5.7531 mL
10 mM 0.1151 mL 0.5753 mL 1.1506 mL 2.3012 mL 2.8765 mL
50 mM 0.023 mL 0.1151 mL 0.2301 mL 0.4602 mL 0.5753 mL
100 mM 0.0115 mL 0.0575 mL 0.1151 mL 0.2301 mL 0.2877 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University

Background on Astragaloside I

Astragaloside I is a natural product isolated from Astragalus.

References:
[1]. JIN Yi-qun, et al. Determination of astragaloside-I content in Qidan Jiannao Granules with HPLC-ELSD. Acta Chinese Medicine and Pharmacology, 2006-02 [2]. Wang chunhong, et al. Determination the Content of Astragaloside I in Shuxing Oral by Dual Wavelength TLC-Scanning. China Pharmacist, 2005-05

Featured Products
New Products
 

References on Astragaloside I

Protective effects of astragalus extract against intermittent hypoxia-induced hippocampal neurons impairment in rats.[Pubmed:23595393]

Chin Med J (Engl). 2013;126(8):1551-4.

BACKGROUND: Intermittent hypoxia is the main pathophysiological cause of the obstructive sleep apnea syndrome. Astragalus shows improvement of spatial learning and memory abilities under intermittent hypoxia. Our study aimed to investigate the protective effect of astragalus against intermittent hypoxia induced-hippocampal neurons impairment in rats and lay the theoretical foundation for the sleep apnea improvement in cognitive function by astragalus. METHODS: Male Wistar rats were divided into 4 groups: blank control group, normoxia group, intermittent hypoxia group and astragalus treated intermittent hypoxia group. After 6-week treatment, apoptosis of neurons was evaluated by terminal deoxynucleotidyl-transferase-mediated dUTP nick end-labeling (TUNEL) assay. Furthermore, the expression of HIF-1a was detected by real-time reverse transcription polymerase chain reaction (RT-PCR) at the mRNA level as well as by immunohistochemistry (IHC) and Western blotting at the protein level. RESULTS: HPLC analysis indicated that Astragaloside IV, Astragaloside II and Astragaloside I were the main compounds in astragals extract. Astragalus extract reduced the apoptosis of hippocampal neurons (P < 0.05) and decreased the expression of HIF-1a at both the mRNA and protein levels in hippocampus compared with non-treated groups (P < 0.05). CONCLUSION: Astragalus protects against intermittent hypoxia-induced hippocampal neurons impairment in rats.

Astragaloside I Stimulates Osteoblast Differentiation Through the Wnt/beta-catenin Signaling Pathway.[Pubmed:27397144]

Phytother Res. 2016 Oct;30(10):1680-1688.

Astragaloside I (As-I), one of the main active ingredients in Astragalus membranaceus, is believed to have osteogenic properties, but this hypothesis has not been investigated in detail. In the present work, the As-I-induced osteogenic effects and its underlying mechanism were studied in MC3T3-E1 cells. The results indicated that the cellular levels of ALP and extracellular matrix calcium increased in a dose-dependent manner by As-I. To clarify the mechanisms involved in this process, the effect of As-I on the key osteogenic-related genes was investigated. We found that As-I stimulated the expression of beta-catenin and Runx2 in MC3T3-E1 cells, which play central roles in the Wnt/beta-catenin signaling pathway, suggesting that As-I could promote osteoblastic differentiation by regulating the Wnt/beta-catenin signaling pathway. Moreover, the osteogenic effect of As-I could be inhibited by DKK-1, which is the classical inhibitor of Wnt/beta-catenin-signaling pathway. Furthermore, As-I also increased BMP-2, BGP and OPG/RANKL expression, which are also activated by Wnt/beta-catenin signaling pathway. Taken together, our findings show that As-I stimulates osteoblast differentiation through the Wnt/beta-catenin signaling pathway, which also activates the BMP pathway and RANK pathway, thus highlighting the As-I for pharmaceutical and medicinal applications such as treating bone disease. Copyright (c) 2016 John Wiley & Sons, Ltd.

Description

Astragaloside I is a natural product isolated from Astragalus.

Keywords:

Astragaloside I,84680-75-1,Astrasieversianin IV; Cyclosieversioside B;91739-00-3,Natural Products, buy Astragaloside I , Astragaloside I supplier , purchase Astragaloside I , Astragaloside I cost , Astragaloside I manufacturer , order Astragaloside I , high purity Astragaloside I

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result:

      BioCrick BioTech
      88# Keyuan road,Hi-Tech Zone
      Chengdu, Sichuan 610042, PRC
      Email: info@biocrick.com
      Tel:86-28-8543-3893
      Follow us:

      BioCrick is one of the biggest natural products manufacturers in Asia

      Our products can be used as reference standards,inhibitors in pharmacological research

      Our MISSION is to provide Best-in-class High-purity natural compounds to researchers all around the world

      © 2007-2024 BioCrick BioTech. All rights reserved.  sitemap

      Menu Close
      Search Now